

# 2018 Reflux Esophagitis/GERD Drug Development- Pipeline Analysis Report

<https://marketpublishers.com/r/25C6D0B1D84EN.html>

Date: May 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 25C6D0B1D84EN

## Abstracts

With an estimated 25 million people being affected by Reflux Esophagitis/GERD in the US, it is considered as one of the most common GI Disorders. GERD causes stomach contents regurgitate into the esophagus, causing damage to esophagus.

Around 30 companies and universities are focusing on developing treatment options for Reflux Esophagitis/GERD.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Reflux Esophagitis/GERD pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Reflux Esophagitis/GERD pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Reflux Esophagitis/GERD pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

## Contents

### 1 TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

### 2 REFLUX ESOPHAGITIS/GERD PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Reflux Esophagitis/GERD Pipeline Snapshot

2.3 Reflux Esophagitis/GERD Pipeline by Phase

2.4 Reflux Esophagitis/GERD Pipeline by Company

2.5 Reflux Esophagitis/GERD Pipeline by Mechanism of Action

### 3 REFLUX ESOPHAGITIS/GERD- COMPANY WISE PIPELINE ANALYSIS

Cancer Advances Inc

CJ HealthCare

Daewoong Pharmaceutical Co

Effexus Pharmaceutical

Eisai Co Ltd

Il-Yang Pharm.Co.,Ltd

Ironwood Pharmaceuticals

Jeil Pharmaceutical Co Ltd

Jiangsu Aosaikang Pharmaceutical

Mitsubishi Pharma Corporation

New Haven Pharmaceuticals

Pfizer

RaQualia Pharma Inc

Renexxion LLC

Rottapharm

Takeda Pharmaceutical Co

Trio Medicines Ltd

Yooyoung Pharm Co Ltd

Yuyu Pharma Inc

### 4 REFLUX ESOPHAGITIS/GERD R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details  
Therapeutic Candidate Name  
Originator  
Co-Developer/License Partner  
Orphan Drug Designation  
Development Phase  
Mechanism of Action  
Current Status  
Ongoing Clinical Trial Details

## **5 RECENT DEVELOPMENTS IN REFLUX ESOPHAGITIS/GERD PIPELINE**

## **6 APPENDIX**

- 6.1 About VPA Research
- 6.2 Sources and Research Methodology

## List Of Figures

### LIST OF FIGURES

- Figure 1: Reflux Esophagitis/GERD Pipeline by Phase, H1- 2018
- Figure 2: Reflux Esophagitis/GERD Pipeline by Companies, H1- 2018
- Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
- Figure 4: Reflux Esophagitis/GERD Pipeline by Mechanism of Action, H1- 2018
- Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

## List Of Tables

### LIST OF TABLES

- Table 1: Reflux Esophagitis/GERD Pipeline by Phase, H1- 2018
- Table 2: Reflux Esophagitis/GERD Pipeline by Companies, H1- 2018
- Table 3: Reflux Esophagitis/GERD Pipeline by Mechanism of Action, H1- 2018
- Table 4: Cancer Advances Inc Reflux Esophagitis/GERD Pipeline, May 2018
- Table 5: CJ HealthCare Reflux Esophagitis/GERD Pipeline, May 2018
- Table 6: Daewoong Pharmaceutical Co Reflux Esophagitis/GERD Pipeline, May 2018
- Table 7: Effexus Pharmaceutical Reflux Esophagitis/GERD Pipeline, May 2018
- Table 8: Eisai Co Ltd Reflux Esophagitis/GERD Pipeline, May 2018
- Table 9: Eisai Co Ltd Reflux Esophagitis/GERD Pipeline, May 2018
- Table 10: Il-Yang Pharm.Co.,Ltd Reflux Esophagitis/GERD Pipeline, May 2018
- Table 11: Ironwood Pharmaceuticals Reflux Esophagitis/GERD Pipeline, May 2018
- Table 12: Jeil Pharmaceutical Co Ltd Reflux Esophagitis/GERD Pipeline, May 2018
- Table 13: Jiangsu Aosaikang Pharmaceutical Reflux Esophagitis/GERD Pipeline, May 2018
- Table 14: Mitsubishi Pharma Corporation Reflux Esophagitis/GERD Pipeline, May 2018
- Table 15: New Haven Pharmaceuticals Reflux Esophagitis/GERD Pipeline, May 2018
- Table 16: Pfizer Reflux Esophagitis/GERD Pipeline, May 2018
- Table 17: RaQualia Pharma Inc Reflux Esophagitis/GERD Pipeline, May 2018
- Table 18: Renexxion LLC Reflux Esophagitis/GERD Pipeline, May 2018
- Table 19: Rottapharm Reflux Esophagitis/GERD Pipeline, May 2018
- Table 20: Takeda Pharmaceutical Co Reflux Esophagitis/GERD Pipeline, May 2018
- Table 21: Trio Medicines Ltd Reflux Esophagitis/GERD Pipeline, May 2018
- Table 22: Yooyoung Pharm Co Ltd Reflux Esophagitis/GERD Pipeline, May 2018

## I would like to order

Product name: 2018 Reflux Esophagitis/GERD Drug Development- Pipeline Analysis Report

Product link: <https://marketpublishers.com/r/25C6D0B1D84EN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/25C6D0B1D84EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970